Snezhkova, Elisaveta, Rodionova, Natalia, Bilko, Dennis, Silvestre-Albero, Joaquín, Sydorenko, Alexey, Yurchenko, Olga, Pakharenko, Marharyta, Alavijeh, Mo, Bardakhivska, Kvitoslava, Riabchenko, Natalia, Nikolaev, Vladimir
Orally Administered Activated Charcoal as a Medical Countermeasure for Acute Radiation Syndrome in Rats
Snezhkova E, Rodionova N, Bilko D, Silvestre-Albero J, Sydorenko A, Yurchenko O, Pakharenko M, Alavijeh M, Bardakhivska K, Riabchenko N, Nikolaev V. Orally Administered Activated Charcoal as a Medical Countermeasure for Acute Radiation Syndrome in Rats. Applied Sciences. 2021; 11(7):3174. https://doi.org/10.3390/app11073174
URI: http://hdl.handle.net/10045/114287
DOI: 10.3390/app11073174
ISSN: 2076-3417
Abstract: 
Activated charcoal (AC) can be taken orally as enterosorbent for treatment of pathological states related to exogenous and endogenous intoxications. Synthesized granulated AC with a highly developed active surface (SBET ~2700 m2/g) was used as a medical countermeasure (MCM) to acute radiation sickness (ARS) in rats after total body X-ray irradiation. AC demonstrates positive results in ARS treatment, as expressed in, (i) a decrease in body weight loss, (ii) a protection of bone marrow (BM) cells colony formation capacity, (iii) a reduction of BM chromosomal aberrations and small intestine and spleen tissue damage, (iv) an amelioration of white blood cell count, and (v) a mitigation of superoxide ion generation rate in the liver. AC oral prescription seems to be perspective modality of ARS treatment.
Keywords:Activated charcoal, Enterosorbent, Acute radiation sickness, Rats
MDPI
info:eu-repo/semantics/article